Efficacy of Duspatalin® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups

P. Guyot

Home Medicine Efficacy of Duspatalin® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups

Chapter

Licensed

Unlicensed Requires Authentication

Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups

P. Guyot

Published by

Become an author with De Gruyter Brill

Explore this Subject How to publish with us

This chapter is in the book Clinical Implications of Irritable Bowel Syndrome

MLA
APA
Harvard
Chicago
Vancouver

MLA
APA
Harvard
Chicago
Vancouver

Guyot, P.. "Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups". Clinical Implications of Irritable Bowel Syndrome, edited by Philippe Denis, Berlin, Boston: De Gruyter, 1997, pp. 39-48. https://doi.org/10.1515/9783110803907-006

Guyot, P. (1997). Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups. In P. Denis (Ed.), Clinical Implications of Irritable Bowel Syndrome (pp. 39-48). Berlin, Boston: De Gruyter. https://doi.org/10.1515/9783110803907-006

Guyot, P. 1997. Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups. In: Denis, P. ed. Clinical Implications of Irritable Bowel Syndrome. Berlin, Boston: De Gruyter, pp. 39-48. https://doi.org/10.1515/9783110803907-006

Guyot, P.. "Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups" In Clinical Implications of Irritable Bowel Syndrome edited by Philippe Denis, 39-48. Berlin, Boston: De Gruyter, 1997. https://doi.org/10.1515/9783110803907-006

Guyot P. Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups. In: Denis P (ed.) Clinical Implications of Irritable Bowel Syndrome. Berlin, Boston: De Gruyter; 1997. p.39-48. https://doi.org/10.1515/9783110803907-006

Copy

Copied to clipboard

BibTeX EndNote RIS

You are currently not able to access this content.

Chapters in this book

Frontmatter I
Authors III
Contents V
Introduction 1
Psychosocial aspects of functional gastrointestinal disorders 3
Abdominal pain in gastrointestinal disorders — differences between IBS and other gastrointestinal disorders 17
Visceral sensitivity: What are the perspectives for the clinician? 29
Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups 39
Clinical experience with mebeverine 200 mg 49

Search book Search the content of this book

https://doi.org/10.1515/9783110803907-006

Chapters in this book

Frontmatter I
Authors III
Contents V
Introduction 1
Psychosocial aspects of functional gastrointestinal disorders 3
Abdominal pain in gastrointestinal disorders — differences between IBS and other gastrointestinal disorders 17
Visceral sensitivity: What are the perspectives for the clinician? 29
Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups 39
Clinical experience with mebeverine 200 mg 49

Efficacy of Duspatalin® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups

Chapter PDF View

Chapters in this book

Chapters in this book

Chapters in this book

Efficacy of Duspatalin^® 200 mg in patients with irritable bowel syndrome: Results of a descriptive study on various symptom subgroups